Interpace Biosciences Inc Sustainability Reports
Interpace Biosciences Inc. provides molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk for patients with indeterminate biopsies. The company develops and commercializes genomic tests, such as PancraGEN, ThyGeNEXT, and ThyraMIR, to personalize medicine and improve clinical management.
Sector: Healthcare & social services
Country: United States
Exchange: OTC Markets
LEI: 5493006LRJROHHZJM864
FIGI: BBG001S6S681
2 reports from 2020 to 2022
